R327 COVID Study Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- Expansion and Acceleration of Clinical Programs
- Appendix 4E
- Phase I Clinical Trial of R327 I.V. - 6000mg Complete
- Corporate Presentation - Aussie Equities Day 2022
- Phase I Positive Safety Data - 4000mg Complete
Later from Recce Pharmaceuticals
- Pause in trading
- Anti-Infective Portfolio Update and Webinar details
- Approval to Start Phase I/II Diabetic Foot Ulcer Study
- Anti-Infective Research Unit est. at Murdoch Childrens
- Australian Patent to be Granted for RECCE Anti-Infectives
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals